1 Tegar

Cystic Fibrosis Case Study For A 6 Year Old

1. Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun. 2011;25:386–94.[PubMed]

2. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45(Suppl 2):II1–II5.[PMC free article][PubMed]

3. Koloski NA, Jones M, Kalantar J, Welt-man M, Zaguirre J, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61:1284–90.[PubMed]

4. Campo JV, Jansen-McWilliams L, Comer DM, Kelleher KJ. Somatization in pediatric primary care: association with psychopathology, functional impairment, and use of services. J Am Acad Child Adolesc Psychiatry. 1999;38:1093–101.[PubMed]

5. Wasserman AL, Whitington PF, Rivara FP. Psychogenic basis for abdominal pain in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1988;27:179–84.[PubMed]

6. Campo JV, Bridge J, Lucas A, et al. Physical and emotional health of mothers of youth with functional abdominal pain. Arch Pediatr Adolesc Med. 2007;161:131–7.[PubMed]

7. Braaten E, Felopulos G. Nonverbal learning disorders and Asperger syndrome. In: Braaten E, Felopolus G, editors. Straight talk about psychological testing for kids. New York: Guilford Press; 2004. pp. 151–77.

8. Diagnostic and statistical manual of mental disorders, rev: DSM-IV-R. 4. Washington, DC: American Psychiatric Association; 2000.

9. Pynnönen PA, Isometsä ET, Aronen ET, Verkasalo MA, Savilahti E, Aalberg VA. Mental disorders in adolescents with celiac disease. Psychosomatics. 2004;45:325–35.[PubMed]

10. García-Manzanares A, Lucendo AJ. Nutritional and dietary aspects of celiac disease. Nutr Clin Pract. 2011;26:163–73.[PubMed]

11. Geringer ES, Querques J, Kolodziej MS, Burns TE, Stern TA. Diagnosis and treatment of depression in the intensive care unit patient. In: Irwin RS, Rippe JM, editors. Irwin and Rippe’s intensive care medicine. 7. Philadelphia: Lippincott Williams & Wilkins; 2012. pp. 2087–98.

12. Akiskal HS, Maser JD, Zeller PJ, et al. Switching from ‘unipolar’ to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry. 1995;52:114–23.[PubMed]

13. Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry. 1994;33:461–8.[PubMed]

14. Forty L, Smith D, Jones L, et al. Clinical differences between bipolar and unipolar depression. Br J Psychiatry. 2008;192:388–9.[PubMed]

15. Benazzi F. Classifying mood disorders by age-at-onset instead of polarity. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:86–93.[PubMed]

16. Weissman MM, Wickramaratne P, Nomura Y, et al. Families at high and low risk for depression: a 3-generation study. Arch Gen Psychiatry. 2005;62:29–36.[PubMed]

17. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev. 1998;18:765–94.[PubMed]

18. Rohde P, Lewinsohn PM, Seeley JR. Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults. J Abnorm Psychol. 1991;100:214–22.[PubMed]

19. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132:132–49.[PMC free article][PubMed]

20. Choe CJ, Emslie GJ, Mayes TL. Depression. Child Adolesc Psychiatric Clin N Am. 2012;21:807–29.[PubMed]

21. Birmaher B, Brent D, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503–26.[PubMed]

22. Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36:427–40.[PMC free article][PubMed]

23. Palermo TM, Eccleston C, Lewandowski AS, Williams AC, Morley S. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. Pain. 2010;148:387–97.[PMC free article][PubMed]

24. Antidepressant medications for children and adolescents: information for parents and caregivers. Bethesda, MD: National Institute of Mental Health; 2011. http://www.nimh.nih.gov/health/topics/child-and-adolescent-mental-health.

25. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332–9.[PubMed]

26. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683–96.[PubMed]

27. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807–20.[PubMed]

28. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132–43. Erratum, Arch Gen Psychiatry 2008;65:101. [PubMed]

29. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry. 2009;166:418–26.[PMC free article][PubMed]

30. Vitiello B, Emslie G, Clarke G, et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011;72:388–96.[PMC free article][PubMed]

31. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299:901–13.[PMC free article][PubMed]

32. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–52.[PubMed]

33. Hughes CW, Emslie GJ, Crismon ML, et al. Texas Children’s Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:667–86.[PubMed]

34. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649–57.[PubMed]

35. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185–94.[PubMed]

36. O’Leary C, Walsh CH, Wieneke P, et al. Coeliac disease and autoimmune Addison’s disease: a clinical pitfall. QJM. 2002;95:79–82.[PubMed]

37. Myhre AG, Aarsetøy H, Undlien DE, Hovdenak N, Aksnes L, Husebye ES. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scand J Gastroenterol. 2003;38:511–5.[PubMed]

38. Biagi F, Campanella J, Soriani A, Vailati A, Corazza GR. Prevalence of coeliac disease in Italian patients affected by Addison’s disease. Scand J Gastroenterol. 2006;41:302–5.[PubMed]

39. Betterle C, Lazzarotto F, Spadaccino AC, et al. Celiac disease in North Italian patients with autoimmune Addison’s disease. Eur J Endocrinol. 2006;154:275–9.[PubMed]

40. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010;339:525–31.[PubMed]

41. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068–79.[PubMed]

42. Løväs K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol (Oxf) 2002;56:581–8.[PubMed]

43. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93:400–9.[PMC free article][PubMed]

44. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007;92:3912–22.[PubMed]

45. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013–20.[PubMed]

46. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000;85:4650–6.[PubMed]

47. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676–81.[PubMed]

An adult cystic fibrosis patient presenting with persistent dyspnea: case report

1Medicine-Pediatrics Program, Boonshoft School of Medicine, Wright State University, Suite 500 Elizabeth Place, Dayton, OH, 45408, USA

2Piketon Medical Center, 10 Indian Ridge Drive, Suite 1, Piketon, OH 45661, USA

Corresponding author.

#Contributed equally.

Gary M Onady: ten.lop@ydanomg; Catherine L Farinet: moc.oohay@teniraflc

Author information ►Article notes ►Copyright and License information ►

Received 2006 Jan 11; Accepted 2006 May 8.

Copyright © 2006 Onady and Farinet; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC.



Persistent dyspnea is a common finding in the cystic fibrosis patient that typically leads to further work up of an alternative pulmonary etiology. Adult cystic fibrosis patients; however, are growing in numbers and they are living into the ages in which coronary artery disease becomes prevalent. Coronary disease should be included in the consideration of diagnostic possibilities.

Case presentation

A 52-year-old white male with cystic fibrosis was evaluated for exertional dyspnea associated with vague chest discomfort. Diagnostic testing revealed normal white blood cell, hemoglobin and platelet count, basic metabolic panel, fasting lipid profile, HbA1c, with chest radiograph confirming chronic cystic findings unchanged from prior radiographs and an electrocardiogram that revealed sinus rhythm with left anterior fascicular block. Stress thallium testing demonstrated a reversible anteroseptal perfusion defect with a 55% left ventricular ejection fraction. Heart catheterization found a 99% occlusion of the left anterior descending artery extending into the two diagonal branches, with 100% obstruction of the left anterior descending artery at the trifurcation and 70% lesion affecting the first posterior lateral branch of the circumflex artery.


This case report represents the first description in the medical literature of a cystic fibrosis patient diagnosed with symptomatic coronary artery disease. Applying a standard clinical practice guide proved useful toward evaluating a differential diagnosis for a cystic fibrosis patient presenting with dyspnea and chest discomfort.


Cystic Fibrosis (CF) is the most common lethal inherited disease in the Caucasian population. It was once considered a childhood disease; however, with advances in health care there is a growing population of adults with CF [1]. A life expectancy that was only 8 years of age in 1974 had advanced to the age of 21 years in 1994, and today is estimated as high as 40 years of age [2]. There are patients on the Cystic Fibrosis Foundation Patient Registry in 2003 that are in their eighth decade of life [1].

With new found longevity comes a new spectrum of disease prevalence associated with aging. Cystic Fibrosis Related Diabetes (43% prevalence) is now the number two chronic illness in the adult CF patient following chronic lung disease and surpassing liver disease (24% prevalence) in patients greater than 30 years of age [3]. Cardiovascular disease has been essentially isolated to cor pulmonale as a consequence of end stage obstructive pulmonary disease. Hypertension has not been considered a serious problem in this patient population [4]; however, a 20% prevalence has been observed at our CF adult center. Symptomatic coronary artery disease, one of the most prevalent of diseases in the adult patient population, has never been reported in the CF population from a PubMed literature search to date. Guides for care of health concerns in adult patients with CF were published in a January 2004 Consensus Report to help transition CF health care from pediatrician to internists or other adult care providers [3]. Many aspects of cardiovascular discussions such as hypertension and forms of heart disease separate from cor pulmonale are missing from this consensus report. The following discussion illustrates the need to continually update and add new information that will lead to optimizing the care of adult CF patients.

Case presentation

A 52-year-old white male with CF presented with persistent exertional dyspnea and cough with scant sputum production. Physical examination demonstrated oxygen saturation of 91%, with normal temperature and vital signs. His weight had fallen from 79.2 to 77.1 kg over 3 months. Cardiovascular exam was entirely normal. Lungs demonstrated coarse breath sounds bilaterally with scattered rales throughout the lung fields. The abdomen was normal, extremities demonstrated significant clubbing and there was no peripheral edema. Forced expiratory volume at 1 second (FEV1) had decreased from 50% to 36%. The chest radiograph resembled baseline findings with no obvious infiltrate or pneumothroax. He received a month-long course of azithromycin, aztreonam and inhaled tobramycin for suspected pulmonary exacerbation of acute super-infection in the setting of underlying chronic CF lung disease.

One month later, follow-up revealed no improvement in dyspnea and no change in the scant sputum production, despite full adherence to the antibiotic regimen and airway clearance techniques. Exertional discomfort located along the sternum and left anterior chest associated with dyspnea without radiation or pressure sensation was further described but was not associated with palpitations, diaphoresis or nausea. This discomfort improved with rest and was not associated with meals. He did report the need to sleep upright in a recliner, but denied paroxysmal nocturnal dyspnea.

CF was diagnosed in this patient by sweat chloride at age 35 after an episode of hemoptysis, with subsequent genetic analysis identifying a ΔF508, 2789+5G>A mutation. He also has gastroesophageal reflux, Barrett's esophagus, azoospermia, and pancreatic insufficiency. He had sinus surgery at age 47. Medications include albuterol, ipratropium, fluticasone, dornase alpha, salmeterol, omeprazole, pancreatin and multivitamin. The patient's father had a myocardial infarction at age 37, his mother had coronary artery bypass surgery at 52 years of age, and a brother underwent coronary bypass at age 61. The patient has never smoked and alcohol intake was minimal.

Diagnostic testing demonstrated normal white blood cell, hemoglobin and platelet count. Electrolytes, albumin, protein and glucose were normal with a 5.1% HbA1c. Total cholesterol was 139 mg/dl, LDL 80 mg/dl, HDL 30 mg/dl and triglycerides at 76 mg/dl. Chronic findings with cystic changes were evident on chest radiograph, but with no obvious consolidation. Electrocardiogram revealed sinus rhythm with a left anterior fascicular block and normal ST findings.

Stress thallium testing was subsequently arranged within a week of the follow up visit, with results positive for moderate anteroseptal area of reversible perfusion with a left ventricular ejection fraction of 55%. Subsequent heart catheterization revealed 99% occlusion of the left anterior descending artery with extension into the two diagonal branches, 100% obstruction of the left anterior descending artery at the trifurcation and 70% lesion affecting the first posterior lateral branch of the circumflex artery. The patient was evaluated for possible coronary artery bypass graft; however, because of his current pulmonary status, angioplasty was elected with successful stenting of the left anterior descending artery. On follow up one year out from stent placement, the patient remained asymptomatic with exercise tolerance and pulmonary function returning to baseline.


This is the first report of a cystic fibrosis patient diagnosed with symptomatic coronary artery disease (CAD) and acknowledges that adult cystic fibrosis patients have indeed survived into the years were coronary artery disease becomes prevalent. Therefore, the likelihood of coronary disease should be included in the diagnostic consideration of persistent dyspnea associated with chest discomfort by applying the same standards used in grading a differential with an anginal presentation in non-CF patients [5].

The patient presented in this case had a Framingham score estimate that predicted a 10-year cardiovascular risk at 4% [6]. However, because of the presence of subtle chest discomfort associated with dyspnea, medical decision making includes an active alternative diagnosis of atypical angina based on two of three positive criteria of exertional symptoms with symptom relief upon resting [5]. Persistent dyspnea may be an occasional finding for a cystic fibrosis patient, and one that typically leads to further work up of a pulmonary etiology; however, cardiovascular disease was additionally considered in this patient.

The typical differential diagnosis of persistent dyspnea in an adult cystic fibrosis patient would include pneumothorax (5% prevalence) [7], atypical mycobacterial pneumonia (15% prevalence) [8], allergic bronchopulmonary aspergillosis (30% prevalence) [9], and cor pulmonale (3% prevalence in association with severe CF pulmonary disease) [10]. Without a history for hemoptysis, atypical mycobacterium and allergic bronchopulmonary aspergillosis would be less likely. Physical exam and chest radiograph did not support either pneumothorax or congestive heart failure. Symptoms could also be explained by this patient's progression of gastroesophageal reflux and/or Barrett's esophagus.

Atypical angina would be the most prevalent differential diagnosis, at 60%, for our patient's clinical presentation of chest pain in the non-CF male patient at this age [5]. The risk of CAD is not typically considered as an active alternative diagnosis for the CF patient; yet with aging, even CF patients will be at risk for CAD. This risk may even be greater given higher prevalence of known risk factors such as diabetes mellitus in the CF versus non-CF patient [11].

Two cases of asymptomatic coronary artery disease have been reported in association with CF with some advanced detail. One case came to diagnosis at autopsy, characterized as generalized atherosclerosis in a 41-year-old female CF patient [homozygous G542X] with diabetes mellitus that died from respiratory failure [12]. Further review of this case revealed a 200 mg/dl averaged cholesterol level, progressive hypertension with biopsy proven nephrosclerosis by 31-years of age, and a diabetic course complicated by gastrointestinal pseudoparesis, retinopathy and neuropathy. In this case, coronary artery disease was an incidental finding on autopsy as she was asymptomatic for myocardial ischemia during her lifetime.

A second case was described in which segmental hypokinesis with grade 2 systolic function was found as an incidental finding on Doppler echocardiography from a prevalence study looking at pulmonary hypertension that included an adult cystic fibrosis patient population [10]. This study identified a 40-year-old diabetic male, diagnosed with asymptomatic coronary artery disease after performing a thallium perfusion scan. Further testing by cardiac catheterization was not reported in this study.

What about other coronary risk factors? Cholesterol and hypertension were not identified risk factors present in our patient. The autopsy case report had several risk factors present, most notably, diabetes and hypertension, but with only a borderline elevated cholesterol level. What is the expected lipid level in a CF patient? The largest lipid study conducted on a CF population reported 134 ± 84 mg/dl triacylglycerol and 138 ± 84 mg/dl total cholesterol values [14]. Only 4% of patients had cholesterol levels >200 mg/dl in this study, with a maximum total cholesterol identified at 240 mg/dl. Serum cholesterol levels can be highly variable in CF patients. Patients with pancreatic insufficiency have low to normal cholesterol levels even with a high fat diet and enzyme supplementation as seen in this case [15]; however, CF patients with pancreatic sufficiency are likely at the same risk as the general population for complications for hyperlipidemia [16]. Another study of aortic atherosclerosis in CF patients found that they have less fatty streaking of the aorta than their weight matched counterparts [17]. Clearly there are other factors that may lead to atherosclerosis than lipid levels; however, applying a clinical practice guide published by the American College of Physicians [5] proved helpful toward diagnosing CAD in this CF patient presenting with dyspnea associated with a chest discomfort.


CF – cystic fibrosis; FEV1 – forced expiratory volume at 1 second; LDL – low density lipoprotein; HDL – high density lipoprotein; CAD – coronary artery disease;

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

GMO contributed to the literature review cited in the discussion and editing of the original manuscript. CLF providing medical care for the patient described in this case presentation, and wrote the original manuscript detailing the clinical findings encountered from the clinical assessment. All authors read and approved the final manuscript.


The authors used no additional resources in preparing this manuscript. Written consent was obtained from the patient for publication of this study.


  • Cystic Fibrosis Foundation . Patient registry annual data report 2003. Bethesda MD: Cystic Fibrosis Foundation; 2003.
  • Fogarty A, Hubard R, Britton J. International comparison of median age at death from cystic fibrosis. Chest. 2000;117:1656–1660. doi: 10.1378/chest.117.6.1656.[PubMed][Cross Ref]
  • Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodmann D. Cystic fibrosis adult care consensus conference report. Chest. 2004;125[PubMed]
  • Super M, Irtiza-Ali A, Roberts SA, Scharz M, Young M, Smith A, Roberts T, Hinks J, Heagerty A. Blood pressure and the cystic fibrosis gene: evidence for lower pressure rises with age in female carriers. Hypertension. 2004;44:878–883. doi: 10.1161/01.HYP.0000145901.81989.46.[PubMed][Cross Ref]
  • Panzer RJ. Diagnostic strategies for common medical problems, Coronary Artery Disease. American College of Physicians Press, Philadelphia, PA; 1991. pp. 44–45.
  • Framingham point scores US Department of Health and Human Service. National Institutes of Health, National Heart, Lung and Blood Institute. NIH Publication No 01-3305.
  • Kuster P, Bender SW, Posselt HG, Stover B, Wiesemann HG. Spontaneous pneumothorax in cystic fibrosis. Monatsschr Kinderheilkd. 1988;136:251–255.[PubMed]
  • Pierre-Audigier CP, Feroni A, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, Vu-Thien H, Fauroux B, Mariani P, Munck A, Bingen E, Guillemot D, Quesne G, Vincent V, Berche P, Gaillard JL. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Micro. 2005;43:3467–3470. doi: 10.1128/JCM.43.7.3467-3470.2005.[PMC free article][PubMed][Cross Ref]
  • Fink JN, Kelly J. Immunologic aspects of granulomatous and interstitial lung diseases and of cystic fibrosis. JAMA. 1992;268:2874–2881. doi: 10.1001/jama.268.20.2874.[PubMed][Cross Ref]
  • Fraser KL, Tullis E, Sason Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fobrosis. Chest. 1999;115:1321–1328. doi: 10.1378/chest.115.5.1321.[PubMed][Cross Ref]
  • Hayes FJ, O'Brien C, FitzGerald MX, McKenna MS. Diabetes mellitus in an adult cystic fibrosis population. Ir Med J. 1994;87:59–60.[PubMed]
  • Schlesinger DM, Holsclaw DS, Fyfe B. Generalized atherosclerosis in an adult with CF and diabetes mellitus [abstract] Eleventh Annual North American Cystic Fibrosis Conference, Nashville, Tennessee, October 23–26, 1997.
  • Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock IP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest. 1998;113:576–583.[PubMed]
  • Milla C, Parks EF, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr. 2002;75:1005–1011.[PubMed]
  • Stewart C, Wilson DC, Hanna AK, Corey M. Lipid metabolism in adults with cystic fibrosis [abstract] Eleventh Annual North American Cystic Fibrosis Conference, Nashville, Tennessee, October 23–26, 1997.
  • Slesinski MJ, Gloninger MF, Costantino JP, Orenstein DM. Lipid levels in adults with cystic fibrosis. J Am Dietetic Assoc. 1994;94:402–408. doi: 10.1016/0002-8223(94)90095-7.[PubMed][Cross Ref]
  • Holman RL, Blanc W, Anderson D. Decreased aortic atherosclerosis in cystic fibrosis of the pancreas. Pediatrics. 1959;24:34–39.[PubMed]

Articles from BMC Pulmonary Medicine are provided here courtesy of BioMed Central

Leave a Comment


Your email address will not be published. Required fields are marked *